Myagmarsuren, Erdenetuya
Loading...
Товч нэр
Myagmarsuren, Erdenetuya
Бүтэн нэр
Myagmarsuren Erdenetuya
Латин нэр
Myagmarsuren Erdenetuya
Албан тушаал
Судлаач
ORCID
2 results
Now showing 1 - 2 of 2
- Some of the metrics are blocked by yourconsent settings
Item type:Publication, Management of Cardiovascular Medicines Used at the Regional Diagnostic and Treatment Center of the Western Region of Mongolia(2021-04-13) ;Dulmaa Lkhagvasuren; ; As cardiovascular diseases are the major global health problem, the management of cardiovascular medicines (CVMs) should not be out of attention. We aimed to identify CVMs needing strict management control, used in 2017 and 2018 to investigate if there was a possibility to make savings in the expenditure for CVMs if the proper management was done regarding Class A medicines at the Regional Diagnostic Treatment Center of Khovd aimag in 2018. Aggregate data methods, Always, Better and Control (ABC), Vital, Essential and Non-essential (VEN), and ABC-VEN matrix analyses were used to identify the categories of CVMs, included in the Essential Medicine List of Mongolia for the year 2017 and 2018. Class A medicines represented 23.81% and 30.43% of the total CVMs and consumed the largest proportion of the total budgets at 73% and 71% in 2017 and 2018, respectively. The Category I, which requires strict management control, contains the majority (an average of 59%) of total CVMs and amounting for an average of 78.67% of total expenditures in 2017 and 2018. We conclude that the Regional Diagnostic and Treatment Center could have saved a total of 6,646,500 MNT if the proper management regarding Class A medicines was done in 2018 based on the results of ABC, VEN, and ABC-VEN matrix analyses of 2017. - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Biochemical and Hematological Patterns of Hospitalized COVID-19 Patients in Mongolia(Mongolian National University of Medical Sciences, 2023-11-06); ; ; Objectives: The impact of COVID-19 prompted a race to find a treatment that would reduce its mortality. This study aimed to analyze how the clinical and laboratory characteristics reflect the disease process and progression of COVID-19 cases in hospitalized patients of Mongolia, which could be informative in managing patients with COVID-19. Methods: A cross-sectional study was conducted on the prescription patterns of drugs given to hospitalized patients diagnosed with COVID-19. A total of 1012 participants were recruited in the study. These were identified from the reported positive cases by polymerase chain reaction or antigen reactivity performed in Ulaanbaatar. Result: A total of 1096 patients participated in this study. The mean age was 51.86 ± 16.98 for male patients and 52.23 ± 16.4 for female patients. It has been revealed that there are statistically significant differences between male and female patients. RBC was 4.56 ± 0.79 M/ UL and 5.08 ± 1.36 M/UL, men and women respectively. The levels of C-reactive protein (CRP) in female COVID-19 patients were significantly higher (46.75 ± 72.83 mg/dL) compared to male patients (33.94 ± 47.96 mg/dL). The platelet count (PLT) was 245.32 ± 77.71 for male patients, while there was a significant reduction in PLT count in female patients (229.30 ± 71.59). Conclusions: Patients with COVID-19 in Mongolia appeared to remain in the hospital for 6.86 ± 2.43 days, shorter than in other countries. Hematological analysis showed that female patients had elevated C-reactive protein levels and decreased PLT count.
